<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39343247</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.</ArticleTitle><Pagination><StartPage>106285</StartPage><MedlinePgn>106285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2024.106285</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(24)00219-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Response data for COVID-19 vaccines in immunosuppressed individuals are typically limited to standard dosing in small populations. Adjusting number or interval of doses may impact immune responses based on HIV status.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This phase 2 randomised, observer-blinded, placebo-controlled South African study (2019nCoV-505/NCT05112848) enrolled medically stable people living with HIV (PLWH) and HIV-uninfected participants aged 18-65 years. PLWH were randomised 1:1:1 to receive NVX-CoV2373 on day 0 (D0) and either D21 (2-Dose<sub>D0/D21</sub>) or D70 (2-Dose<sub>D0/D70</sub>), or on D0, D21, and D70 (3-Dose). HIV-uninfected participants were randomised 1:1 to each 2-Dose regimen. PLWH were stratified into well-controlled and less-well-controlled subgroups. The primary immunologic endpoint included serum IgG and neutralising antibody responses (per geometric mean fold rise [GMFR] in titre and seroconversion rate) to ancestral SARS-CoV-2 at D35 (2-Dose<sub>D0/D21</sub>) and D84 (2-Dose<sub>D0/D70</sub> and 3-Dose). The primary safety endpoints were participants with an unsolicited adverse event through D84, at D120, and at D180, or reactogenicity ≤7 days post-vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 288 PLWH, 98, 96, and 94 were randomised into the 2-Dose<sub>D0/D21</sub>, 2-Dose<sub>D0/D70</sub>, and 3-Dose groups, respectively; 96 HIV-uninfected participants were randomised to the 2-Dose<sub>D0/D21</sub> (n = 47) or 2-Dose<sub>D0/D70</sub> (n = 49) regimens. Most (&gt;85%) of the population were SARS-CoV-2 positive at baseline. Ancestral anti-spike IgG GMFRs in PLWH and HIV-uninfected participants, respectively, were 12·4 and 12·9 (D35) and 12·2 and 13·6 (D84). Comparable outcomes occurred across dosing regimens and in well-controlled and less-well-controlled PLWH. Microneutralization GMFRs at D84 in PLWH and HIV-uninfected participants, respectively, were: 6·9 and 10·1 (2-Dose<sub>D0/D21</sub>), 11·0 and 11·3 (2-Dose<sub>D0/D70</sub>), and 17·2 (PLWH 3-Dose). Antibody responses against BA.1 trended similar to those against the ancestral virus. Safety outcomes were comparable among PLWH and HIV-uninfected participants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated that NVX-CoV2373 produced consistent immunogenicity responses to SARS-CoV-2 among PLWH and HIV-uninfected participants, with no new safety signals.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Chijioke</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novavax, Inc., 700 Quince Orchard Road, Gaithersburg, MD 20878, USA. Electronic address: cbennett@novavax.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoosain</LastName><ForeName>Zaheer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Josha Research, 28 East Burger Street, Bloemfontein 9301, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koen</LastName><ForeName>Anthonet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Sherwell and Beit Street, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalloo</LastName><ForeName>Umesh</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>KwaPhila Health Solutions (Enhancing Care), 16 Charles Strachan Road, Berea, Durban 4091, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louw</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Madibeng Centre for Research, 40 Pienaar Street Madibeng, Brits 0250, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maluleke</LastName><ForeName>Vongane</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Mzansi Ethical Research Centre (MERC), 184 Cowen Ntuli St, Middelburg 1055, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Faeezah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street Hillbrow, Johannesburg 2001, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benade</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street Hillbrow, Johannesburg 2001, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venter</LastName><ForeName>Esme Louise</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>The Aurum Institute-Pretoria CRS, 6 Mark Shuttleworth Street, Pretoria 0182, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galbiati</LastName><ForeName>Shirley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novavax, Inc., 700 Quince Orchard Road, Gaithersburg, MD 20878, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinde</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Novavax, Inc., 700 Quince Orchard Road, Gaithersburg, MD 20878, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhi</LastName><ForeName>Shabir A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Sherwell and Beit Street, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Study 2019nCoV-505 Investigators Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CB, VS, and SG are employees of Novavax, Inc. and as such receive a work salary and hold Novavax stock. UL receives honoraria from Astra-Zeneca, Glaxo-Smith Kline, Apsen, and Novartis for lectures unrelated to this study and is a principal investigator for the Druban International Clinical Research Site of Adult AIDS Clinical Trials Group of the United States National Institutes of Health. SAM reports receiving grant support paid to his institution from Novavax (related to this study) and from BMGF, Pfizer, Glaxo-Smith Kline, and Minervax (unrelated to this study); and honoraria to his institution from Sanofi for lectures (unrelated this study). ZH, AK, CL, ELV, VM, FP, and GB have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39343247</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2024.106285</ArticleId><ArticleId IdType="pii">S0163-4453(24)00219-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle>